Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 8/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MIF | P14174 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17655082 | 0.91 | GLS (0.80) | GLS | |
| SCHEMBL17193491 | 0.87 | GLS (0.82) | GLSLMNAALDH1A1POLBMEN1 | |
| SCHEMBL17193288 | 0.86 | GLS (0.80) | GLSLMNAALDH1A1POLBMEN1 | |
| SCHEMBL5345562 | 0.85 | GLS (0.67) | GLSLMNAALDH1A1POLBMEN1 | |
| SCHEMBL15724893 | 0.84 | GLS (0.67) | GLS | |
| SCHEMBL17655081 | 0.83 | GLS (0.68) | GLS | |
| SCHEMBL15724908 | 0.83 | SMN1; SMN2 (0.72) | GLSLMNAALDH1A1POLBKDM4E | |
| SCHEMBL1011592 | 0.83 | POLB (0.68) | GLSLMNAALDH1A1POLBMEN1 | |
| SCHEMBL17193292 | 0.81 | GLS (0.64) | GLSLMNAALDH1A1POLBMEN1 | |
| SCHEMBL17193289 | 0.81 | GLS (0.64) | GLSLMNAALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | GLS, GLS2, GLUL | GLS 1/4885LMNA 4026/4885ALDH1A1 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.